ConductScience.org, home

Comparison · NCT00683800-d8f2f6e2

DVS SR 100 mg vs Placebo: Number of Participants With Adjudicated Cerebrovascular Events - Probable TIA

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. DVS SR 100 mg vs Placebo: Number of Participants With Adjudicated Cerebrovascular Events - Probable TIA. Trial comparisons, record NCT00683800-d8f2f6e2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00683800-d8f2f6e2

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.0009380.0001660.00529wilson
Risk in group 2000.00364wilson
Risk difference, group 1 minus group 20.000938-0.002780.00529newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treat, for one more participant with the outcome on DVS SR 100 mg than on Placebo1,066from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1DVS SR 100 mgDesvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal.11,066OG000
Group 2PlaceboMatching placebo tablets daily until Day 365 or early withdrawal.01,052OG001

Outcome

Type
OTHER_PRE_SPECIFIED
Title
Number of Participants With Adjudicated Cerebrovascular Events - Probable TIA
Description
Adjudicated cerebrovascular events were identified using Standardized MedDRA Query (SMQ), for central nervous system haemorrhages and cerebrovascular conditions. Primary assessments included: 1) definite stroke, 2) probable stroke, 3) probable transient ischemic attack (TIA), and 4) no stroke or TIA.
Time frame
Baseline up to Month 12
Population
Safety population included all randomized participants who received at least 1 dose of study medication.

Source ClinicalTrials.gov

Trial

Title
Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women
NCT number
NCT00683800
Phases
PHASE3
Conditions
Vasomotor Symptoms
Interventions
desvenlafaxine succinate (DVS) SR, Placebo
Lead sponsor
Pfizer
Results first posted
2011-08-17

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00683800-d8f2f6e2